<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intravenous thrombolytic therapy for acute ischemic stroke: Therapeutic use</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jamary Oliveira-Filho, MD, MS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Owen B Samuels, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">José Biller, MD, FACP, FAAN, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alejandro A Rabinstein, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H548313"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The most important factor in successful reperfusion therapy of acute ischemic stroke is early treatment. Nonetheless, selection of appropriate candidates for reperfusion demands a neurologic evaluation and a neuroimaging study. In addition, reperfusion therapy for acute stroke requires a system that coordinates emergency services, stroke neurology, intensive care services, neuroimaging, and neurosurgery to provide optimal treatment.</p><p>This topic will review the administration of intravenous thrombolytic therapy for patients with acute ischemic stroke. The approach to reperfusion therapy and selection of appropriate patients for treatment is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a>.)</p><p>Mechanical thrombectomy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/115663.html" rel="external">"Mechanical thrombectomy for acute ischemic stroke"</a>.)</p><p>Other aspects of acute ischemic stroke care are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a> and  <a class="medical medical_review" href="/d/html/1085.html" rel="external">"Neuroimaging of acute stroke"</a>.)</p><p class="headingAnchor" id="H3091727280"><span class="h1">OVERVIEW OF REPERFUSION THERAPY</span><span class="headingEndMark"> — </span>The immediate goal of reperfusion therapy for acute ischemic stroke is to restore blood flow to the regions of brain that are ischemic but not yet infarcted. The long-term goal is to improve outcome by reducing stroke-related disability and mortality. There are two options for reperfusion therapy that are proven effective:</p><p class="headingAnchor" id="H3211990670"><span class="h2">Intravenous thrombolytic therapy</span><span class="headingEndMark"> — </span>Thrombolytic therapy is the mainstay of treatment for acute ischemic stroke. Because the benefit is time-dependent, it is critical to treat eligible patients as quickly as possible.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment within 4.5 hours</strong> – Intravenous thrombolysis improves functional outcome for patients with acute ischemic stroke, provided that treatment is initiated within 4.5 hours of clearly defined symptom onset time or within 4.5 hours of the time the patient was last known to be well  (<a class="graphic graphic_table graphicRef71462" href="/d/graphic/71462.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef141876" href="/d/graphic/141876.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Benefit by time to treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wake-up stroke or unknown time of symptom onset</strong> – For patients with wake-up stroke or unknown time last known well, imaging-based criteria to determine eligibility for intravenous thrombolysis (ie, an MRI showing an acute ischemic lesion that is diffusion positive and fluid-attenuated inversion recovery [FLAIR] negative) is an option at expert stroke centers to determine eligibility for intravenous thrombolysis. (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Benefit with imaging selection of patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">Alteplase</a> – Alteplase, a recombinant tissue plasminogen activator (tPA), initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converting entrapped plasminogen to plasmin. In turn, plasmin breaks up the thrombus. The pivotal randomized trials that established the efficacy of intravenous thrombolytic therapy for acute stroke used alteplase as the thrombolytic agent. (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Alteplase'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">Tenecteplase</a> – Tenecteplase is a thrombolytic agent that is more fibrin-specific and has a longer duration of action compared with <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>. Although not licensed in the United States for intravenous thrombolysis in acute ischemic stroke treatment, there is evidence that intravenous tenecteplase has similar efficacy and safety outcomes compared with alteplase. (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Tenecteplase'</a>.)</p><p></p><p class="headingAnchor" id="H2610144906"><span class="h2">Mechanical thrombectomy</span><span class="headingEndMark"> — </span>Mechanical thrombectomy is indicated for patients with acute ischemic stroke due to a large artery occlusion in the anterior circulation who can be treated within 24 hours of the time last known to be well (ie, at neurologic baseline), regardless of whether they receive intravenous thrombolysis for the same ischemic stroke event  (<a class="graphic graphic_algorithm graphicRef141874" href="/d/graphic/141874.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/115663.html" rel="external">"Mechanical thrombectomy for acute ischemic stroke"</a>.)</p><p>Eligible patients should receive intravenous thrombolysis without delay even if mechanical thrombectomy is being considered [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H548362"><span class="h1">ADMINISTRATION OF THROMBOLYTIC THERAPY</span><span class="headingEndMark"> — </span>"Time is brain." The sooner intravenous thrombolysis is initiated after ischemic stroke, the more likely it is to be beneficial. The benefits and risks of thrombolytic therapy with <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> or <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> are discussed in detail separately (see  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke"</a>). The selection of appropriate patients for such therapy is summarized in the table  (<a class="graphic graphic_table graphicRef71462" href="/d/graphic/71462.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef141876" href="/d/graphic/141876.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H4135885641"><span class="h2">Preparing for treatment</span><span class="headingEndMark"> — </span>Prior to treatment, all patients require confirmation of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis is acute ischemic stroke</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment is commencing within the required 4.5-hour time window after the onset of symptoms, defined as the time last seen normal or at baseline</p><p class="bulletIndent1"><span class="glyph">●</span>There is a persistent, measurable, disabling neurologic deficit</p><p class="bulletIndent1"><span class="glyph">●</span>Eligibility criteria are met  (<a class="graphic graphic_table graphicRef71462" href="/d/graphic/71462.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum glucose must be checked to rule out hypoglycemia as a cause of neurologic deficit</p><p class="bulletIndent1"><span class="glyph">●</span>The noncontrast head computed tomography (CT) or brain magnetic resonance imaging (MRI) is without hemorrhage or other contraindication</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure parameters are met (see <a class="local">'Management of blood pressure'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Two intravenous lines, preferably large bore, are in place</p><p class="bulletIndent1"><span class="glyph">●</span>Accurate body weight has been determined [<a href="#rid2">2</a>]</p><p></p><p class="headingAnchor" id="H2033684512"><span class="h2">Management of blood pressure</span><span class="headingEndMark"> — </span>Strict blood pressure control is critical prior to and during the first 24 hours after thrombolytic therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>The blood pressure must be at or below 185 mmHg systolic and 110 mmHg diastolic before administering thrombolysis. Patients with blood pressure above this range should be treated with intravenous agents such as intravenous <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a> or <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a>, or <a class="drug drug_general" data-topicid="8911" href="/d/drug information/8911.html" rel="external">clevidipine</a>  (<a class="graphic graphic_table graphicRef50725" href="/d/graphic/50725.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. Alternative agents include <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> and <a class="drug drug_general" data-topicid="17094" href="/d/drug information/17094.html" rel="external">enalaprilat</a>. If intravenous treatment does not bring the blood pressure into the acceptable range, the patient should not be treated with thrombolysis because the risk of intracerebral hemorrhage with thrombolytic therapy may be increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once thrombolytic therapy has been administered, the blood pressure must be maintained below 180/105 mmHg during and for 24 hours following thrombolytic therapy  (<a class="graphic graphic_table graphicRef50725" href="/d/graphic/50725.html" rel="external">table 2</a>). Intravenous <a class="drug drug_general" data-topicid="9540" href="/d/drug information/9540.html" rel="external">labetalol</a>, <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a>, or <a class="drug drug_general" data-topicid="8911" href="/d/drug information/8911.html" rel="external">clevidipine</a> are suggested agents of first choice [<a href="#rid1">1</a>]. Frequent blood pressure monitoring is recommended to ensure that the blood pressure remains in the acceptable range. Current guidelines recommend monitoring every 15 minutes for the first 2 hours after starting thrombolytic treatment, then every 30 minutes for the next 6 hours, then every hour until 24 hours after starting treatment. The frequency of blood pressure monitoring should be increased if the systolic blood pressure is &gt;180 mmHg or if the diastolic blood pressure is &gt;105 mmHg.</p><p></p><p>For patients with stroke caused by a known large artery occlusion (documented by computed tomography angiography [CTA] or magnetic resonance angiography [MRA]), we suggest keeping systolic blood pressure between 150 to 180 mmHg prior to reperfusion, and targeting systolic blood pressure to &lt;140 mmHg once reperfusion is achieved with intravenous thrombolysis or mechanical thrombectomy (see  <a class="medical medical_review" href="/d/html/115663.html" rel="external">"Mechanical thrombectomy for acute ischemic stroke", section on 'Blood pressure'</a>). These recommendations regarding blood pressure control are based on consensus, since there are no data supporting the use of any specific antihypertensive agent or regimen for patients with acute ischemic stroke treated with thrombolysis.</p><p>The optimal lower end of the range of desired blood pressure is unclear in those requiring antihypertensive treatment for thrombolysis. Maintaining the blood pressure below 180/105 mmHg for at least the first 24 hours after administration of thrombolytic therapy is the only guideline recommendation [<a href="#rid1">1</a>]. In this situation, there is still a risk of worsening blood flow within the ischemic penumbra if blood pressure is driven too low. Therefore, it is important to avoid excessive blood pressure lowering when using intravenous antihypertensive treatment.</p><p>Despite concerns about reducing perfusion, more intensive blood pressure reduction might reduce the risk of symptomatic intracerebral hemorrhage and thereby improve outcomes. The blood pressure control assessment arm of the open-label, international ENCHANTED trial tested this strategy and found that a target blood pressure of 130 to 140 mmHg with intravenous thrombolytic therapy did not appear to be beneficial or harmful. The ENCHANTED trial enrolled over 2200 alteplase-eligible patients with acute ischemic stroke and randomly assigned them to intensive blood pressure lowering (to a target systolic blood pressure of 130 to 140 mmHg within one hour) or guideline blood pressure lowering (target &lt;180 mmHg) over 72 hours [<a href="#rid3">3</a>]. The mean systolic blood pressure over 24 hours in the intensive and guideline groups was 144.3 mmHg and 149.8 mmHg, respectively. At 90 days, there was no difference in functional status between groups. Intracranial hemorrhage was less frequent in the intensive group compared with the guideline group (14.8 versus 18.7 percent), but there was no significant difference between groups in rates of symptomatic intracerebral hemorrhage or serious adverse events.</p><p class="headingAnchor" id="H550917"><span class="h2">Dosing</span></p><p class="headingAnchor" id="H2093342397"><span class="h3">Alteplase dose</span><span class="headingEndMark"> — </span>A dedicated intravenous line is required for <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>, and all patients should have at least one additional large bore intravenous line.</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> dose is calculated at 0.9 mg/kg of actual body weight, with a maximum dose of 90 mg</p><p class="bulletIndent1"><span class="glyph">●</span>Ten percent of the dose is given as an intravenous bolus over one minute and the remainder is infused over one hour</p><p></p><p>It is advisable to remove any excess <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> from the bottle prior to administration, in order to avoid overdosage if the intravenous pump is inaccurately calibrated.</p><p>In Japan, the approved dose of <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> for acute ischemic stroke is 0.6 mg/kg, based upon the results of a small open-label study suggesting that this dose was associated with a lower risk of intracerebral hemorrhage and similar efficacy compared with the standard alteplase dose of 0.9 mg/kg [<a href="#rid4">4</a>]. However, in the ENCHANTED trial, which enrolled over 3300 subjects (63 percent Asian) with acute ischemic stroke, low-dose alteplase (0.6 mg/kg) did <strong>not</strong> meet noninferiority criteria compared with standard-dose alteplase (0.9 mg/kg) for the outcome of death and disability at 90 days [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2473935583"><span class="h3">Tenecteplase dose</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> is 0.25 mg/kg (maximum total dose 25 mg) given in a single intravenous bolus over 5 seconds, followed by a <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> flush [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H550924"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>All patients treated with intravenous thrombolysis for acute ischemic stroke should be admitted to an intensive care unit or dedicated stroke unit for at least 24 hours of close neurologic and cardiac monitoring [<a href="#rid1">1</a>]. Symptomatic intracerebral hemorrhage should be suspected in any patient who develops sudden neurologic deterioration, a decline in level of consciousness, new headache, nausea and vomiting, or a sudden rise in blood pressure after thrombolytic therapy is administered, especially within the first 24 hours of treatment. (See <a class="local">'Management of symptomatic intracerebral hemorrhage'</a> below.)</p><p>Important measures during the first 24 hours of treatment with thrombolytic therapy include the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vital signs and neurologic status should be checked every 15 minutes for two hours, then every 30 minutes for six hours, then every 60 minutes until 24 hours from the start of thrombolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure must be maintained at or below 180/105 mmHg during the first 24 hours. (See <a class="local">'Management of blood pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombotic agents, such as heparin, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants, or antiplatelet drugs, should <strong>not</strong> be administered for at least 24 hours after the <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> infusion or <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> bolus is completed, unless their administration is absolutely necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Placement of intra-arterial catheters, indwelling bladder catheters, and nasogastric tubes should be avoided for at least 24 hours if the patient can be safely managed without them.</p><p></p><p>A follow-up noncontrast CT (or MRI) brain scan should be obtained 24 hours after thrombolysis is initiated before starting treatment with antiplatelet or anticoagulant agents [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H549875"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The most feared complication of thrombolytic therapy is symptomatic intracerebral hemorrhage. Asymptomatic intracerebral hemorrhage, systemic bleeding, and angioedema are additional complications that may arise.</p><p class="headingAnchor" id="H33561301"><span class="h2">Intracerebral hemorrhage</span><span class="headingEndMark"> — </span>Treatment with intravenous (IV) thrombolysis within 4.5 hours of acute ischemic stroke onset is associated with an increased early risk of intracerebral hemorrhage, which was in the range of 5 to 7 percent; lower rates have been observed using stricter definitions of symptomatic intracerebral hemorrhage. This risk is offset by later benefit in the form of reduced disability. (See  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Alteplase'</a> and  <a class="medical medical_review" href="/d/html/115775.html" rel="external">"Approach to reperfusion therapy for acute ischemic stroke", section on 'Risk of intracerebral hemorrhage'</a>.)</p><p class="headingAnchor" id="H549640"><span class="h2">Management of symptomatic intracerebral hemorrhage</span><span class="headingEndMark"> — </span>Symptomatic intracerebral hemorrhage should be suspected in any patient who develops sudden neurologic deterioration, a decline in level of consciousness, new headache, nausea and vomiting, or a sudden rise in blood pressure after thrombolytic therapy is administered, especially within the first 24 hours of treatment.</p><p>In patients with suspected intracerebral hemorrhage, the <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> infusion should be discontinued and a stat noncontrast head computed tomography (CT) or magnetic resonance imaging (MRI) scan should be arranged  (<a class="graphic graphic_table graphicRef68717" href="/d/graphic/68717.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Blood should be drawn for typing and cross matching, and measurement of prothrombin time, activated partial thromboplastin time, platelet count, and fibrinogen.</p><p>Treatment options for intracerebral hemorrhage related to intravenous thrombolytic treatment are unproven but include the administration of agents to reverse the effects of thrombolytic therapy and antithrombotic therapy [<a href="#rid1">1,8-13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cryoprecipitate, 10 units immediately (infused over 10 to 30 minutes) and more as needed to achieve a serum fibrinogen level of 150 to 200 mg/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Antifibrinolytic agents: <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a> 4 to 5 g IV during first hour, followed by 1 g/hour for 8 hours until bleeding is controlled, <strong>or </strong><a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> 10 to 15 mg/kg IV over 10 to 20 minutes</p><p class="bulletIndent1"><span class="glyph">●</span>Prothrombin complex concentrate as adjunctive therapy to cryoprecipitate for patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> prior to thrombolytic treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Fresh frozen plasma as adjunctive therapy to cryoprecipitate for patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> prior to thrombolytic treatment if prothrombin complex concentrate is not available</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/d/drug information/9771.html" rel="external">Vitamin K</a> as adjunctive therapy for patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> prior to thrombolytic treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Six to eight units of platelets for patients with thrombocytopenia (platelet count &lt;100,000/microL)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients receiving <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) for any reason, it is reasonable to treat with 1 mg of protamine for every 100 units of UFH given in the preceding 4 hours</p><p></p><p>Urgent neurosurgery and hematology consultations are indicated for patients with symptomatic intracranial hemorrhage associated with thrombolysis [<a href="#rid1">1</a>]. Supportive therapy includes management of blood pressure, intracranial pressure, cerebral perfusion pressure, and glucose control.</p><p>The efficacy of neurosurgical evacuation in this setting is unproven. However, in a retrospective analysis of data from the GUSTO-I trial of thrombolysis for myocardial infarction, 30-day survival was significantly higher with neurosurgical hematoma evacuation than without (65 versus 35 percent), and there was a trend towards improved functional outcome due to a higher incidence of nondisabling stroke in those with evacuation compared with those without (20 versus 12 percent) [<a href="#rid14">14</a>]. However, no definitive conclusions can be drawn from this retrospective, nonrandomized study.</p><p class="headingAnchor" id="H549655"><span class="h2">Systemic bleeding</span><span class="headingEndMark"> — </span>Mild systemic bleeding usually occurs in the form of oozing from intravenous catheter sites, ecchymoses (especially under automated blood pressure cuffs), and gum bleeding; these complications do not require cessation of treatment. More serious bleeding, such as from the gastrointestinal or genitourinary system, may require discontinuation of <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> depending on the severity.</p><p>Rarely, patients who suffer stroke after a recent myocardial infarction can develop bleeding into the pericardium, resulting in life-threatening tamponade [<a href="#rid15">15,16</a>]. Consequently, patients who become hypotensive after thrombolytic therapy should be evaluated with urgent echocardiography.</p><p class="headingAnchor" id="H549662"><span class="h2">Angioedema</span><span class="headingEndMark"> — </span>Orolingual angioedema occurs in 1 to 8 percent of patients treated with <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> or <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> for ischemic stroke [<a href="#rid17">17-20</a>], and it is typically mild, transient, and contralateral to the ischemic hemisphere [<a href="#rid18">18,21</a>]. Patients taking angiotensin converting enzyme inhibitors and those with CT evidence of ischemia in the frontal and insular cortex may be at increased risk.</p><p>Severe orolingual angioedema is rare but may cause partial airway obstruction and require emergent airway management [<a href="#rid1">1,18,21,22</a>]. CT of the tongue can distinguish hematoma from angioedema in this setting [<a href="#rid23">23</a>].</p><p>The patient with angioedema near or involving the tongue, uvula, soft palate, or larynx must be immediately assessed for signs of airway compromise. If intubation is necessary, the airway should be managed by the most experienced person available, because intubation in the presence of laryngeal angioedema can be difficult due to distortion of the normal anatomy. Angioedema of the lips or mouth sometimes spreads to involve the throat, and frequent monitoring of airway patency is critical throughout treatment. (See  <a class="medical medical_review" href="/d/html/8105.html" rel="external">"An overview of angioedema: Clinical features, diagnosis, and management"</a>.)</p><p>Treating centers should be aware of the potential need for stopping the drug infusion, administering antihistamines and glucocorticoids, and intubating patients who develop stridor.</p><p>Specific management recommendations for orolingual angioedema include the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintain airway:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endotracheal intubation may not be necessary if edema is limited to anterior tongue and lips. Edema involving larynx, palate, floor of mouth, or oropharynx with rapid progression (within 30 minutes) poses higher risk of requiring intubation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Awake fiberoptic intubation is optimal. Nasotracheal intubation may be necessary but is associated with a risk of epistaxis after treatment with IV thrombolysis. Emergency cricothyrotomy is rarely needed and is also problematic after IV thrombolysis treatment, but in a life-threatening circumstance the need to establish an airway supersedes this concern. (See  <a class="medical medical_review" href="/d/html/275.html" rel="external">"Approach to the difficult airway in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/6391.html" rel="external">"The difficult pediatric airway for emergency medicine"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> infusion and hold angiotensin converting enzyme inhibitor</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Give in rapid sequence:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 125 mg</p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> 50 mg</p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 20 mg</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is further increase in angioedema, give <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> (0.1 percent) 0.3 mL subcutaneously or 0.5 mL by nebulizer, but note that epinephrine has a theoretical risk of blood pressure elevation and hemorrhage</p><p></p><p>Additional treatment options for refractory angioedema include <a class="drug drug_general" data-topicid="16808" href="/d/drug information/16808.html" rel="external">icatibant</a> and <a class="drug drug_general" data-topicid="8998" href="/d/drug information/8998.html" rel="external">plasma-derived C1 inhibitor concentrate</a>, which have been used to treat hereditary angioedema and angiotensin converting enzyme inhibitor-related angioedema [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/16380.html" rel="external">"ACE inhibitor-induced angioedema", section on 'Therapies of unproven efficacy'</a>.)</p><p class="headingAnchor" id="H377592297"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a>.)</p><p class="headingAnchor" id="H28958755"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15328.html" rel="external">"Patient education: Stroke (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/726.html" rel="external">"Patient education: Stroke symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/723.html" rel="external">"Patient education: Ischemic stroke treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H548390"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time is brain</strong> – Intravenous thrombolysis is the mainstay of treatment for acute ischemic stroke, provided that treatment is initiated within 4.5 hours of clearly defined symptom onset. Because the benefit of is time-dependent, it is critical to treat patients as quickly as possible. (See <a class="local">'Overview of reperfusion therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – Prior to treatment, eligibility should be confirmed  (<a class="graphic graphic_table graphicRef71462" href="/d/graphic/71462.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef141876" href="/d/graphic/141876.html" rel="external">algorithm 1</a>), two intravenous lines, preferably large bore, should be placed, and accurate body weight determined. (See <a class="local">'Preparing for treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure management</strong> – Strict blood pressure control is critical prior to and during the first 24 hours after thrombolytic therapy. The blood pressure must be at or below 185/110 mmHg before starting treatment. The blood pressure must be maintained at or below 180/105 mmHg for 24 hours following thrombolytic treatment  (<a class="graphic graphic_table graphicRef50725" href="/d/graphic/50725.html" rel="external">table 2</a>). (See <a class="local">'Management of blood pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a> dose is calculated at 0.9 mg/kg of actual body weight, with a maximum dose of 90 mg. Ten percent of the dose is given as an intravenous bolus over one minute and the remainder is infused over one hour. In Japan, however, the approved dose of alteplase for acute ischemic stroke is 0.6 mg/kg.</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="9955" href="/d/drug information/9955.html" rel="external">tenecteplase</a> dose is 0.25 mg/kg (maximum total dose 25 mg) given in a single intravenous bolus over 5 seconds, followed by a <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> flush. (See <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No antithrombotics for 24 hours</strong> – Treatment with anticoagulant or antiplatelet agents should <strong>not</strong> be started within the first 24 hours of thrombolytic therapy in patients with acute ischemic stroke. Antiplatelet therapy should be started for most patients 24 to 48 hours after thrombolytic therapy. (See <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most feared complication of thrombolytic therapy is symptomatic intracerebral hemorrhage. Asymptomatic intracerebral hemorrhage, systemic bleeding, and angioedema are additional complications that may arise. (See <a class="local">'Complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50:e344.</a></li><li><a class="nounderline abstract_t">Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 2010; 121:1664.</a></li><li><a class="nounderline abstract_t">Anderson CS, Huang Y, Lindley RI, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet 2019; 393:877.</a></li><li><a class="nounderline abstract_t">Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810.</a></li><li><a class="nounderline abstract_t">Anderson CS, Robinson T, Lindley RI, et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. N Engl J Med 2016; 374:2313.</a></li><li><a class="nounderline abstract_t">Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA 2020; 323:1257.</a></li><li><a class="nounderline abstract_t">Mitchell PJ, Yan B, Churilov L, et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet 2022; 400:116.</a></li><li><a class="nounderline abstract_t">Yaghi S, Eisenberger A, Willey JZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol 2014; 71:1181.</a></li><li><a class="nounderline abstract_t">Yaghi S, Boehme AK, Dibu J, et al. Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study. JAMA Neurol 2015; 72:1451.</a></li><li><a class="nounderline abstract_t">French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care 2012; 17:107.</a></li><li><a class="nounderline abstract_t">Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2017; 48:e343.</a></li><li><a class="nounderline abstract_t">Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24:6.</a></li><li><a class="nounderline abstract_t">O'Carroll CB, Aguilar MI. Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications. Neurohospitalist 2015; 5:133.</a></li><li><a class="nounderline abstract_t">Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J 1999; 138:493.</a></li><li><a class="nounderline abstract_t">Kasner SE, Villar-Cordova CE, Tong D, Grotta JC. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology 1998; 50:1857.</a></li><li><a class="nounderline abstract_t">Marto JP, Kauppila LA, Jorge C, et al. Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review. Stroke 2019; 50:2813.</a></li><li><a class="nounderline abstract_t">Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307.</a></li><li><a class="nounderline abstract_t">Hurford R, Rezvani S, Kreimei M, et al. Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatry 2015; 86:520.</a></li><li><a class="nounderline abstract_t">Myslimi F, Caparros F, Dequatre-Ponchelle N, et al. Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia. Stroke 2016; 47:1825.</a></li><li><a class="nounderline abstract_t">Zhong CS, Beharry J, Salazar D, et al. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke. Stroke 2021; 52:1087.</a></li><li><a class="nounderline abstract_t">Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60:1525.</a></li><li><a class="nounderline abstract_t">Chodirker WB. Reactions to alteplase in patients with acute thrombotic stroke. CMAJ 2000; 163:387.</a></li><li><a class="nounderline abstract_t">Engelter ST, Fluri F, Buitrago-Téllez C, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 2005; 252:1167.</a></li></ol></div><div id="topicVersionRevision">Topic 16134 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662037" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308619" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30739745" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161018" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078683" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35810757" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25069522" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501741" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22311234" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097489" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26714677" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26288671" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10467200" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633741" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31436141" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883405" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25016564" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27197851" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Orolingual Angioedema During or After Thrombolysis for Cerebral Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33588597" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743244" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976251" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reactions to alteplase in patients with acute thrombotic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16184341" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
